To compare drug having pain relieving action given via regional method versus given intravenously after block in patients undergoing forearm surgeries

A prospective study of comparison of analgesic efficacy of perineural dexamethasone as an adjuvant in supraclavicular block versus intravenous dexamethasone and paracetamol after supraclavicular block in patients undergoing forearm surgeries. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/067262

Enrollment

Registered

2024-05-14

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Dexamethason: Perineural dexamethasone 8mg given in supraclavicular block, for the duration of surgery lasting 3-4 hours Control Intervention1: DEXAMETHASONE: Intravenous dexamethasone

Eligibility

Inclusion criteria

Inclusion criteria: 1.ASA grade 1 and ASA grade 2 fit patients. 2.Patients posted for upper limb surgeries below shoulder 3. Hemodynamically stable patients with all routine investigations within normal limits. 4. Written informed consent from the concerned patients.

Exclusion criteria

Exclusion criteria: Patients whose parents are not willing to participate in the study. 2. Patients with ASA grade III and above physical status. 3. Patients who are aged more than 60 years and less than 18 years of age 4. Patients with known allergy to the study drugs. 5. Patients with bleeding disorders and those on anticoagulant therapy 6. Infection at site of block 7. Neurodeficit involving brachial plexus 8. Pregnant women 9. Patients with psychiatric behavior

Design outcomes

Primary

Measure	Time frame
To compare the analgesic efficacy of perineural dexamethasone as an adjuvant in supraclavicular block versus intravenous dexamethasone and paracetamol after supraclavicular block in patients undergoing forearm surgeries.Timepoint: After administration of the block, comparison between the two groups of onset and duration of sensory and motor blockade, duration of analgesia and time to rescue to analgesia will be assessed at baseline, after injection of study drug, at 5 mins, 10 mins, 15 mins, 30 mins and 10 mins after surgery.	—

Measure

Time frame

To compare the analgesic efficacy of perineural dexamethasone as an adjuvant in supraclavicular block versus intravenous dexamethasone and paracetamol after supraclavicular block in patients undergoing forearm surgeries.Timepoint: After administration of the block, comparison between the two groups of onset and duration of sensory and motor blockade, duration of analgesia and time to rescue to analgesia will be assessed at baseline, after injection of study drug, at 5 mins, 10 mins, 15 mins, 30 mins and 10 mins after surgery.

—

Secondary

Measure	Time frame
To compare the analgesic efficacy of perineural dexamethasone as an adjuvant in supraclavicular block versus intravenous dexamethasone & paracetamol after supraclavicular block in patients undergoing forearm surgeries.Timepoint: Duration of analgesia will be assessed post surgery once the effects of the block decrease & time to rescue to analgesia will be assessed 2 hours after surgery & hourly until intervention is required	—

Measure

Time frame

To compare the analgesic efficacy of perineural dexamethasone as an adjuvant in supraclavicular block versus intravenous dexamethasone & paracetamol after supraclavicular block in patients undergoing forearm surgeries.Timepoint: Duration of analgesia will be assessed post surgery once the effects of the block decrease & time to rescue to analgesia will be assessed 2 hours after surgery & hourly until intervention is required

—

Countries

India

Contacts

Public ContactDr Chhaya Suryawanshi

DR. D.Y.PATIL MEDICAL COLLEGE, HOSPITAL AND RESEARCH CENTRE, PIMPRI, PUNE

chhayasuryawanshi@gmail.com9922888201

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026